Domestic erythropoietin market contested by 3 pharmaceutical firms

Published: 2004-10-14 07:00:00

Updated: 2004-10-14 07:00:00

Business sources says that the domestic erythropoietin (EPO) market has emerged as an arena of tripartite competition CJ Corporation's Epokine, Choong-wae Pharm's Recormon (Roche licensing-in) and Daiichi-Kirin's Aranesp, as the market size is expected to grow to 33.0 billion next year with an a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK